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Background. Despite earlier studies describing the feasibility of steroid weaning in heart transplant patients, the majority of patients
are maintained on steroid therapy for life. We examined a strategy based on a single morning serum cortisol measurement. Methods.
We assigned stable posttransplant patients, who were maintained on tacrolimus, mycophenolate mofetil, and corticosteroids, into
one of two groups based on a screening morning cortisol level. Patients with a cortisol < 8 micrograms/deciliter were assigned to a
“maintenance” group and the others were assigned to the weaning group and steroids were tapered off over 4–6 weeks. Patients were
monitored on subsequent office visits for adrenal insufficiency and allograft rejection. Results. Thirty-one patients were enrolled
(6 patients in the maintenance group and 25 in the steroid-weaning group). Mean follow-up was 10.2 ± 4 years for the weaning
group and 9.0 ± 4.9 years in the maintenance group (𝑝 = 0.6). No cases of rejection were noted, nor did any patient resume steroid
treatment following discontinuation. Conclusion. Steroids can be safely discontinued in stable heart transplant patients with an AM
serum cortisol ≥ 8 micrograms/deciliter with appropriate outpatient follow-up. In this study, no patient suffered late rejection or
clinically noted adrenal insufficiency.

1. Introduction
Corticosteroids have been an integral part of immunosuppression regimens since the beginnings of clinical transplantation [1, 2]. The first heart transplant patients were treated
with corticosteroids and antiproliferative medications such
as azathioprine. With the addition of cyclosporine A to
corticosteroids and antiproliferative drugs [3], heart transplantation changed from a medical experiment to a viable
approach to the treatment of end-stage heart failure [4, 5]. The
complications of long-term steroid use are well known. While
some early studies described the feasibility of steroid weaning
[6–10], the idea has not been embraced, and International
Society for Heart and Lung Transplantation (ISHLT) registry
data indicates that more than 60% of patients are chronically
maintained on corticosteroids [11]. The fear of allograft
rejection and the concern about “unmasking” occult adrenal
insufficiency are the main clinical reasons that more patients
are not routinely discontinued from steroid therapy [7, 12, 13].

In the setting of tacrolimus-based immunosuppression,
others have reported success with steroid-weaning posttransplantation [14–16]. The ISHLT Guidelines for the Care
of Heart Transplant Recipients indicate that corticosteroid
weaning is reasonable, especially in patients with significant
side effects [17]. However, there are no data in heart transplant
recipients to predict which patients will manifest clinical
signs of adrenal insufficiency due to chronic steroid therapy.
Administration of corticosteroids suppresses the hypothalamic-pituitary-adrenal (HPA) axis, and ways to assess
this include the following: morning serum cortisol level,
synthetic adrenocorticotropic hormone (ACTH) stimulation
test, ovine corticotrophin releasing hormone (CRH) stimulation test, and insulin-induced hypoglycemia [18]. While
both CRH and cortisol levels may be more reliable than
ACTH testing [19, 20], an attempt at identifying a specific
threshold for steroid withdrawal has been made only with
serum cortisol level [19]. Use of the ACTH stimulation test
has been reported in kidney transplant patients, but this
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Figure 1: Study flow diagram.

test requires multiple blood draws and synthetic ACTH
is expensive [21]. Using the serum cortisol test to guide
withdrawal of corticosteroids in heart transplant recipients
has not been reported previously.
It was hypothesized that a single morning cortisol measurement could identify stable heart transplant recipients
who could be successfully removed from steroids.

2. Methods
Adult heart transplant recipients who were chronically maintained on tacrolimus, mycophenolate mofetil, and corticosteroids and were at least 4 months after transplant were
eligible for study enrollment. Patients were recruited from
April 2004 to February 2005. All patients were chronically
receiving prednisone at a dose between 2.5 and 10 milligrams
daily. Exclusion criteria included recipients of a second transplant, combined heart-kidney transplants, treated allograft
rejection in the preceding six months, or prior evidence of
adrenal failure. Patients who were receiving cyclosporinebased therapy were excluded as well. The study protocol was
approved by the local Institutional Review Board.
After informed consent, subjects had a comprehensive
metabolic panel including serum sodium, potassium, blood
urea nitrogen, and creatinine. In addition, a serum cortisol
level was drawn prior to 9 AM.

We arbitrarily picked a threshold value of 8 micrograms/deciliter based on prior publications and clinical
experience [18, 19]. There are no studies which have used this
approach in the past, with most reported work utilizing a
cortisol stimulation test.
If a patient’s serum cortisol was less than 8 micrograms/deciliter then the patient was assigned to the “maintenance” group, and corticosteroid dosage was maintained.
The serum cortisol was repeated if the value was close to the
cut point. For those patients with cortisol levels at or above
8 micrograms/deciliter, steroids were weaned to discontinuation over 4–6 weeks as an outpatient. Three patients refused to
discontinue steroids, despite adequate serum cortisol values,
and were excluded from further analysis. Figure 1 shows the
study enrollment graphically.
After study entry, patients were monitored at each visit
for signs of adrenal insufficiency (overt fatigue, muscle aches,
dizziness, or syncope). We did not employ a symptom
questionnaire or routinely check orthostatic blood pressure
measurements. In addition, the patients underwent standard
posttransplant screening including biopsies, serum sodium,
calcium, phosphorus, and magnesium as indicated. Cardiac
biopsies were performed at least once after complete steroid
discontinuation.
The aims of the study were to validate the use of morning serum cortisol level as a simple test for hypothalamic
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Table 1: Baseline demographics.

Demographics
Male, 𝑛 (%)
Female, 𝑛 (%)
Mean age at transplant
Mean baseline prednisone dose
Baseline cortisol level (𝜇g/dL)
Baseline creatinine (mg/dL)
Time after transplant to study entry
Ischemic cardiomyopathy 𝑛 (%)
African American 𝑛 (%)
Pretransplant diabetes mellitus 𝑛 (%)
History of smoking 𝑛 (%)
Statin use (after transplant)

Maintenance group (𝑛 = 6)
5 (83%)
1 (16.7%)
54.5 ± 11.3 years (37–69)
5.8 ± 2.5 mg (2.5–10)
4.8 ± 2.2 (0.5–6.5)
1.4 ± 0.2 (1.2–1.8)
2.2 ± 2.0 years (0.3–5.5)
3 (50%)
2 (33%)
2 (33%)
3 (50%)
6 (100%)

Weaning group (𝑛 = 25)
21 (84%)
4 (16%)
55 ± 10 years (38–69)
4.6 ± 1.5 mg (2.5–10)
13.2 ± 3.9 (8.1–22.4)
1.4 ± 0.4 (0.8–2.2)
1.9 ± 1.5 years (0.3–4.9)
13 (52%)
7 (28%)
3 (12%)
16 (64%)
25 (100%)

pituitary-adrenal axis competency, as well as examining the
clinical outcomes following steroid weaning including the
risk of late rejection and death.

𝑝 value
0.97
0.97
0.92
0.13
<0.0001
0.9
0.68
0.93
0.99
0.24
0.78
NS
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From April 2004 to February 2005, 34 eligible adult heart
transplant patients were enrolled. Subsequently, 3 patients
declined to wean corticosteroids regardless of the protocol
and they were excluded from further analysis. Six patients had
a morning serum cortisol less than 8 micrograms/deciliter
and were assigned to the maintenance group, and 25 patients
were assigned to the steroid-weaning group.
The baseline demographics of the study groups are in
Table 1. There were no significant differences between the
group characteristics. Mean follow-up from date of study
entry to death or July 2017 was 10.2 ± 4 years for the weaning
group and 9.0±4.9 years in the maintenance group (𝑝 = 0.61,
𝑡-test).
Figure 2(a) shows the distribution of morning cortisol
measurements in this study. The median cortisol in the
weaning group was 12 (IQR 10.4–16.3) 𝜇g/dL and 5.55 (IQR
3.7–6.0) for the patients maintained on long-term corticosteroids (𝑝 < 0.0001). The mean cortisol was 11.5 ± 4.9 with
the 95% confidence intervals at 9.7–13.3 𝜇g/dL. The vertical
line shows the prospectively chosen level of 8 mcg/dL which
appears to be an appropriate cut point to distinguish between
groups. Figure 2(b) shows the distribution of baseline cortisol
values between groups demonstrating little overlap between
groups.
Patients had at least one endomyocardial biopsy in the
first 2 months following steroid discontinuation. There were
no cases of rejection (ISHLT grade 2R or higher) noted,
and no patient resumed steroid therapy following discontinuation. No episodes of antibody mediated rejection or
unexplained graft dysfunction were seen in this cohort of
patients.
Survival after study enrollment was examined and is
illustrated in Figure 3. In Figure 3(a), the survival of the
cohort from the date of transplantation to death or July 2017 is

p < 0.0001
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Figure 2

depicted. Figure 3(b) shows survival beginning on the day of
study consent, ending in death or July 2017 which represents
approximately 10 years of follow-up. The survival of the
steroid-weaning group was not significantly different from
that of the corticosteroid maintenance group, but the analysis
is hampered by a small sample size (grossly underpowered for
mortality).
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Figure 3: Survival after study enrollment.

4. Discussion
This is the first prospective trial of corticosteroid weaning in
stable heart transplant patients guided by a laboratory measurement. The widely available serum cortisol measurement
facilitated selection of patients where steroid discontinuation
was well tolerated. Importantly, no patient suffered allograft
rejection, nor graft dysfunction (such as might be seen with
antibody mediated rejection). These results are strengthened
by an average follow-up of approximately 10 years. Patients
were screened for symptoms of adrenal insufficiency at clinic
follow-up visits and none were noted. Long-term follow-up
supports the efficacy and safety of this approach.
The choice of 8 ng/dL was made based on best judgement
and the scant literature which exists. The distribution of the
cortisol values at study entry shows that more than 95% of
patients were above this value, but it is not possible to know
that those with low cortisol could not be successfully weaned
from corticosteroids, since such patients were excluded from
a weaning attempt. Nevertheless, the approach described in
this paper would be applicable to the vast majority of patients
in routine clinical practice.
Most of the patients in the trial were on 5 mg at baseline,
and typically the dose was reduced to zero over a 4–6week period by tapering weekly to 1 mg daily and then 1 mg
every other day and so forth until the patients were free of
corticosteroids. If there was subclinical hypoadrenalism, this
approach would allow gradual improvement of native adrenal
function if possible.
Corticosteroid discontinuation is not a new idea in
transplantation, with reports beginning shortly after the
introduction of cyclosporine [8, 16, 22–24]. However, most
reports demonstrate only moderate success with corticosteroid discontinuation with 25–40% of patients maintained
on corticosteroids long term [25–27]. Most of these studies
have aimed to discontinue steroids over the first year after

transplant, and several have utilized induction antibody
preparations to “facilitate” steroid weaning.
There have been several prospective studies of steroid
weaning early after transplantation. Mehra described outcomes for 41 patients treated with tacrolimus and mycophenolate mofetil. 62% of these patients were withdrawn from
steroids by an average of 20 ± 11 months after transplant.
Meiser et al. reported on 33 patients treated with tacrolimus
and sirolimus and all were successfully discontinued from
steroids by 6 months after transplant [28]. Yamani et al.
published the results for a prospective trial of 32 heart transplant recipients who were randomized to thymoglobulin,
tacrolimus, and mycophenolate mofetil without any maintenance corticosteroids, versus a single dose of thymoglobulin
followed by conventional triple therapy with tacrolimus,
mycophenolate mofetil, and chronic corticosteroids [29].
One of the twelve patients (8%) in the steroid-free group
required long-term steroids due to resistant rejection.
Keogh et al. reported on a prospective trial of cyclosporine/azathioprine and steroids versus cyclosporine and
azathioprine without steroids in 1992 [7]. Approximately half
of the steroid-free patients required institution of chronic
steroids due to rejection however. More recently, CrespoLeiro et al. reported on 24 stable heart transplant recipients
who had not had any acute allograft rejection for at least 4
years and were weaned from corticosteroids in a study [12]. Of
concern, 25% of the patients (6/24) developed ISHLT grade
2R or greater rejection which necessitated treatment with
intravenous steroids, although no episode was fatal. 75% of
the patients were on cyclosporine-based regimens with the
remainder on tacrolimus-based therapy. Castel et al. reported
results for 86 patients who were stable after 24 ± 12 months
after transplant [25]. They were able to discontinue steroids in
63% of the patients, with the most common reason for failure
being acute cellular rejection. Of note, 64% of the patients
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were on tacrolimus but the authors did not correlate drug
regimen to clinical outcomes.
One key difference between the current study and those
in the past is that all patients in this study were receiving
tacrolimus as part of the study entry criteria. Perhaps owing
to higher antirejection potency [30], none of the patients in
this study required resumption of corticosteroid therapy with
an extended follow-up interval. The study is obviously not
powered to assess mortality, but the lack of a negative trend
for the weaning group is encouraging.
The other major result from this study is the utility of
the AM serum cortisol to assess the hypothalamic-pituitary
access in a simple and effective way. None of the patients
with an AM cortisol of at least 8 ng/dL developed clinical
adrenal insufficiency or required a return to corticosteroid
therapy. However, we cannot comment on the patients with
a low cortisol since they were not “challenged” by attempting
steroid withdrawal. In addition, the serum cortisol would not
be expected to have any influence on the patient’s propensity
to experience allograft rejection. The data support the safety
of discontinuing steroids for patients with an AM cortisol
value of at least 8 ng/dL and the distribution of the cortisol
measurements suggests that this is a good discriminator with
very few patients near the cut point.
The benefits of steroid discontinuation have been documented by others and were not systematically assessed in
this study [16, 31, 32]. The number of patients is small and
bone density tests were not universally available. Therefore,
the clinician will need to balance the risks and benefits
for each specific patient but the current study suggests that
discontinuation of steroids is feasible and does not result in
clinical adrenal insufficiency in patients screened with an AM
cortisol measurement. The population is a selected group and
this was not a randomized study.

5. Conclusion
This is the first prospective trial of corticosteroid weaning
guided by a single AM serum cortisol measurement in stable
heart transplant recipients. Steroid weaning in patients with a
serum cortisol ≥ 8 𝜇g/dL was well tolerated with no rejection
or return to corticosteroid therapy over the follow-up period.
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